J.Pharma Research Guide · Recovery Peptides

What is BPC-157?

BPC-157 (Body Protective Compound 157) is a 15-amino acid synthetic peptide derived from a protein found in human gastric juice. It has been one of the most extensively studied peptides in pre-clinical research over the past two decades, with a broad range of investigated biological activities centered on tissue repair, angiogenesis, and anti-inflammatory mechanisms.

Research Use Only. All information on this page is for educational and research reference purposes. J.Pharma products are intended strictly for in vitro laboratory research. Not for human or veterinary use. Not FDA approved for any therapeutic purpose.

What BPC-157 Is

BPC-157 is a pentadecapeptide — a chain of 15 amino acids — that was isolated from a protein found in human gastric juice. Its full designation is Body Protective Compound 157, reflecting its origin in gastric protective research. Unlike many research peptides that are analogues of hormones or growth factors, BPC-157 has no known endogenous human counterpart; it is a synthetic peptide derived from a partial sequence of a gastric protein.

The peptide is water-stable and orally active in animal models, which distinguishes it from many other peptides that are rapidly degraded in the gastrointestinal tract. This stability has made it a subject of considerable research interest for systemic administration routes.

🔬 Key Identification
Molecular formula: C62H98N16O22 · Molecular weight: 1419.5 g/mol · 15 amino acids · CAS: 137525-51-0

Mechanism of Action

Research into BPC-157's mechanism of action has revealed several pathways that may account for its broad range of observed effects in animal models:

Angiogenesis: BPC-157 has been shown to upregulate VEGF (vascular endothelial growth factor) expression and promote the formation of new blood vessels. This is believed to be a primary mechanism by which it accelerates tissue healing in tendon, ligament, and muscle research models — new blood supply to injured tissue is a critical rate-limiting step in repair.

Nitric oxide modulation: Research has demonstrated that BPC-157 modulates nitric oxide (NO) synthesis. It appears to protect endothelial function and may normalize NO signaling disrupted by injury or inflammation.

Growth factor receptor upregulation: Studies have shown BPC-157 upregulates receptors for growth factors including EGF (epidermal growth factor) and increases expression of early response genes involved in tissue repair.

Anti-inflammatory effects: In animal models, BPC-157 has demonstrated reduction of inflammatory markers and protection against inflammation-induced tissue damage across multiple organ systems.

"BPC-157 appears to act as a systemic repair signal — influencing multiple healing pathways simultaneously rather than targeting a single receptor."
Research characterization, pre-clinical models

Research Applications

BPC-157 has been investigated across a remarkably broad range of tissue types and injury models in pre-clinical research:

Research AreaModel TypeObserved Effect
Tendon repairRodent transection modelsAccelerated healing, increased tensile strength
Muscle repairCrush injury modelsReduced recovery time, improved function
Ligament healingTransection modelsImproved structural integrity
GI mucosal protectionNSAID/ethanol modelsReduced ulceration, accelerated healing
Bone healingDefect modelsIncreased bone density at repair site
Corneal repairAlkali burn modelsReduced scarring, improved healing

The breadth of these research applications is unusual among peptides and reflects BPC-157's multi-pathway mechanism of action rather than receptor-specific activity.

BPC-157 + TB500 Combination Research

A common area of research interest is the combination of BPC-157 with TB-500 (synthetic Thymosin Beta-4). The rationale is mechanistic complementarity: BPC-157 is believed to have stronger localized effects at injury sites through angiogenesis and growth factor upregulation, while TB-500 has broader systemic distribution and operates primarily through actin-binding mechanisms that promote cell migration and differentiation.

J.Pharma supplies a pre-combined BPC-157 + TB500 vial (20mg blend) for researchers investigating dual-mechanism tissue repair models.

📦 Available from J.Pharma
BPC-157 + TB500 — 20mg blend vial — $65. Reconstitute with 2mL BAC Water (10mg/mL). View product details →

Reconstitution for Research

BPC-157 is supplied as a lyophilized (freeze-dried) powder and must be reconstituted with Bacteriostatic Water before use in research protocols.

Standard protocol for 20mg BPC-157 + TB500 blend: Add 2mL Bacteriostatic Water to the vial for a 10mg/mL concentration. Inject BAC Water slowly down the vial wall — do not aim directly at the powder cake. The blend may take 60-90 seconds of gentle swirling to fully dissolve. Solution should be clear and colorless. Refrigerate at 2-8°C after reconstitution. Stable 28-42 days.

For full reconstitution parameters and dosing calculator, visit our Reconstitution Guide and Dosing Calculator.

Frequently Asked Questions

What is BPC-157 made from?
BPC-157 is a synthetic 15-amino acid peptide derived from a partial sequence of a protein found in human gastric juice. It is not extracted from biological sources but synthesized in laboratory conditions.
Is BPC-157 the same as TB-500?
No. BPC-157 and TB-500 are distinct peptides with different structures and mechanisms. BPC-157 is a 15-amino acid peptide; TB-500 is the synthetic form of Thymosin Beta-4, a 43-amino acid peptide. They are sometimes combined in research for their potentially complementary mechanisms.
How is BPC-157 stored?
Lyophilized BPC-157 powder can be stored at room temperature or refrigerated (2-8°C). After reconstitution with Bacteriostatic Water, it must be refrigerated at 2-8°C and is stable for 28-42 days. Do not freeze reconstituted peptide.
What concentration should BPC-157 be reconstituted to?
For the 20mg BPC-157 + TB500 blend, standard research protocol uses 2mL Bacteriostatic Water for a 10mg/mL working concentration. Use our dosing calculator at jpharmapeptides.com for exact draw volumes at your target dose.
Regulatory Notice

None of the statements on this website have been reviewed or approved by the U.S. Food and Drug Administration. J.Pharma products are not intended to diagnose, treat, cure, or prevent any disease or medical condition. All products are sold strictly for in vitro laboratory research purposes. They are not for human or animal use of any kind. DiPerna Services, LLC d/b/a J.Pharma is not a compounding pharmacy or outsourcing facility as defined under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act.